See every side of every news story
Published loading...Updated

NervGen Initiates Expanded Access Policy - Life Sciences British Columbia

Summary by lifesciencesbc.ca
The U.S. Food and Drug Administration (FDA) informed the company that an expanded access protocol for NVG-291 may proceed This news release constitutes a “designated news release” for the purposes of NervGen’s prospectus supplement dated December 19, 2024 to its short form base shelf prospectus dated November 25, 2024. VANCOUVER, BC – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neur…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

lifesciencesbc.ca broke the news in on Monday, March 31, 2025.
Sources are mostly out of (0)

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.